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ABSTRACT
Nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) possesses multiple functions in the viral life cycle. NS5A is a phos-
phoprotein that exists in hyperphosphorylated and basally phosphorylated forms. Although the phosphorylation status of NS5A
is considered to have a significant impact on its function, the mechanistic details regulating NS5A phosphorylation, as well as its
exact roles in the HCV life cycle, are still poorly understood. In this study, we screened 404 human protein kinases via in vitro
binding and phosphorylation assays, followed by RNA interference-mediated gene silencing in an HCV cell culture system. Ca-
sein kinase I- (CKI-) was identified as an NS5A-associated kinase involved in NS5A hyperphosphorylation and infectious vi-
rus production. Subcellular fractionation and immunofluorescence confocal microscopy analyses showed that CKI--mediated
hyperphosphorylation of NS5A contributes to the recruitment of NS5A to low-density membrane structures around lipid drop-
lets (LDs) and facilitates its interaction with core protein and the viral assembly. Phospho-proteomic analysis of NS5A with or
without CKI- depletion identified peptide fragments that corresponded to the region located within the low-complexity se-
quence I, which is important for CKI--mediated NS5A hyperphosphorylation. This region contains eight serine residues that
are highly conserved among HCV isolates, and subsequent mutagenesis analysis demonstrated that serine residues at amino ac-
ids 225 and 232 in NS5A (genotype 2a) may be involved in NS5A hyperphosphorylation and hyperphosphorylation-dependent
regulation of virion production. These findings provide insight concerning the functional role of NS5A phosphorylation as a
regulatory switch that modulates its multiple functions in the HCV life cycle.
IMPORTANCE
Mechanisms regulating NS5A phosphorylation and its exact function in the HCV life cycle have not been clearly defined. By us-
ing a high-throughput screening system targeting host protein kinases, we identified CKI- as an NS5A-associated kinase in-
volved in NS5A hyperphosphorylation and the production of infectious virus. Our results suggest that the impact of CKI- in
the HCV life cycle is more profound on virion assembly than viral replication via mediation of NS5A hyperphosphorylation.
CKI--dependent hyperphosphorylation of NS5A plays a role in recruiting NS5A to low-density membrane structures around
LDs and facilitating its interaction with the core for new virus particle formation. By using proteomic approach, we identified
the region within the low-complexity sequence I of NS5A that is involved in NS5A hyperphosphorylation and hyperphosphory-
lation-dependent regulation of infectious virus production. These findings will provide novel mechanistic insights into the roles
of NS5A-associated kinases and NS5A phosphorylation in the HCV life cycle.
Hepatitis C virus (HCV) is a major causative agent of liver-related morbidity and mortality worldwide and represents a
global public health problem (1). An estimated 130 million indi-
viduals are chronically infected with HCV worldwide, and the
treatment of HCV infection imposes a large economic and societal
burden (2). HCV is an enveloped virus with a positive-sense, sin-
gle-stranded RNA genome in the Hepacivirus genus within the
Flaviviridae family (3). The approximately 9.6-kb genome is
translated into a single polypeptide of approximately 3,000 amino
acids (aa), which is cleaved by cellular and viral proteases to pro-
duce the structural proteins (core, E1, E2, and p7) and nonstruc-
tural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
(4). NS3 to NS5B are sufficient for RNA replication in cell culture
(5). NS5B is an RNA-dependent RNA polymerase (RdRp), and
NS3 functions as both an RNA helicase and a serine protease (4).
NS4A is the cofactor of the NS3 protease, and the NS3-NS4A
complex is required for viral precursor processing (4). NS4B in-
duces the formation of a specialized membrane compartment, a
sort of membranous web where viral RNA replication may take
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place (6). NS5A is essential for both viral RNA replication and
virion assembly (7–9).
NS5A is an RNA binding protein and exists as a component of
the replicase complex (10–13). NS5A is phosphorylated on mul-
tiple serine and threonine residues and can be found in hyper-
phosphorylated (p58) and basally phosphorylated (p56) forms
(14–16). Although the distinct mechanisms for generating p56
and p58 forms are still unclear, it has been reported that two re-
gions located around the center and near the C-terminal regions
of NS5A are required for basal phosphorylation, while hyperphos-
phorylation primarily targets serine residues located within low-
complexity sequence I (LCS I), which is the linker between do-
mains I and II (15, 17–19). Several phosphorylation sites have
been mapped in NS5A by using recombinantly expressed protein
and NS5A extracted from cells harboring subgenomic replicons
(20–23).
NS5A phosphorylation plays roles in the regulation of viral
RNA replication and virion assembly. Some of the cell culture-
adaptive mutations in NS4B and NS5A, which reduce NS5A hy-
perphosphorylation, have been found to confer efficient replica-
tion of genotype 1 replicons in Huh-7 cells (17, 18). Similarly,
suppression of NS5A hyperphosphorylation through either the
use of kinase inhibitors or mutagenesis allows higher RNA repli-
cation in non-culture-adapted replicons (18, 24). In contrast,
HCV RNA replication is inhibited after treatment of cells carrying
adapted replicons with the same kinase inhibitor (24). The C-ter-
minal domain III of NS5A is not essential for viral RNA replica-
tion, but it is important for the production of infectious virus.
Alanine replacements of the serine cluster in this domain impair
NS5A phosphorylation, leading to a decrease in NS5A-core pro-
tein interaction, perturbation of the subcellular distribution of
NS5A, and disruption of virion production (7–9).
A number of protein kinases have been identified as having the
ability to phosphorylate NS5A based on comprehensive screening
by using an RNA interference (RNAi) library, recombinantly ex-
pressed kinases, and kinase inhibitors (25–28). Among them, ca-
sein kinase I- (CKI-) and Polo-like kinase 1 (Plk1) have been
shown to play roles in viral RNA replication (25, 27). Although
silencing of CKI- inhibits the replication of the genotype 1b sub-
genomic replicon containing an adaptive mutation (27), its effect
on infectious virus production has not been studied to date. Ca-
sein kinase II (CKII) has been identified as a positive regulator of
virus production via studies with chemical inhibitors and small
interfering RNA (siRNA) (9). However, the functional roles of
NS5A phosphorylation by its associated kinases in regulation of
the viral life cycle are not yet fully understood.
To identify NS5A-associated kinases involved in the HCV life
cycle, we developed an in vitro, high-throughput screening system
for analyzing protein-protein interactions. Using this system fol-
lowed by in vitro phosphorylation assays, we screened human pro-
tein kinases on a kinome-wide scale and identified several NS5A-
associated kinases. siRNA experiments showed that silencing of
CKI- leads to the most marked inhibition of infectious virus
production among the candidate kinases. Here, we report a novel
function of CKI- in the viral life cycle. It is more likely that CKI-
has a more profound impact on virion assembly than on viral
replication through hyperphosphorylation of NS5A. Hyperphos-
phorylated NS5A was predominantly localized in low-density
membrane structures around lipid droplets (LDs), in which NS5A
interacts with the core for virion assembly, while reduction of
NS5A hyperphosphorylation by siRNA targeting CKI- led to a
decrease in NS5A abundance in the low-density membrane struc-
tures. The present study provides important insights into the reg-
ulatory roles of NS5A-associated kinases and NS5A phosphoryla-
tion in the viral life cycle, especially as a molecular switch
governing the transition between viral replication and virion as-
sembly.
MATERIALS AND METHODS
Plasmids. Plasmids pJFH1 and pSGR-JFH1/Luc were generated as previ-
ously described (29, 30). The JFH-1-based Gaussia princeps luciferase
(GLuc) reporter construct, which encodes GLuc followed by the foot-
and-mouth disease virus (FMDV) 2A protein between p7 and NS2, was
generated in a manner similar to the description in a previous report (31).
A 1,042-bp double-stranded DNA fragment containing GLuc (32) and
FMDV 2A (33) sequences flanked by BsaI and NotI sites at its ends was
synthesized and then inserted into the corresponding sites of pJFH1. Re-
lated constructs containing serine-to-alanine or serine-to-aspartic acid
mutations in NS5A were generated using oligonucleotide-directed mu-
tagenesis techniques. To construct pCAG-CKI-, the full-length CKI--
coding sequence was amplified by PCR using cDNAs prepared from
Huh-7 cells. The resulting PCR product was then inserted into the multi-
ple-cloning site of pCAGGS (34). pCAG-CKI-/m6, which contains six
silent point mutations that ablate the binding of CKI- siRNA but main-
tain the wild-type amino acid sequence of CKI-, was generated by oligo-
nucleotide-directed mutagenesis of pCAG-CKI-. All PCR products were
confirmed by automated nucleotide sequencing with an ABI Prism 7000
sequence detection system (Life Technologies, Carlsbad, CA).
Cells. The human hepatoma cell line Huh-7, its derivative cell lines
Huh7.5.1 (35) (a gift from Francis V. Chisari, The Scripps Research Insti-
tute) and Huh7–25 (36), and the human embryonic kidney cell line 293T
used to generate HCV pseudoparticles (HCVpp), were maintained in
Dulbecco modified Eagle medium (DMEM) supplemented with nones-
sential amino acids, 100 U of penicillin/ml, 100 g of streptomycin/ml,
and 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator. SGR-
JFH1/LucNeo cells, which harbor a genotype 2a subgenomic replicon
carrying a firefly luciferase reporter gene fused to the neomycin phospho-
transferase gene of pSGR-JFH1 (37), and LucNeo#2 cells, which harbor a
genotype 1b subgenomic replicon carrying a firefly luciferase/neomycin
phosphotransferase fusion reporter gene (38, 39) (a gift from Koichi
Watashi, National Institute of Infectious Diseases, and Kunitada Shimo-
tohno, National Center for Global Health and Medicine), were cultured in
the above medium supplemented with 300 g/ml G418.
Antibodies. Mouse monoclonal antibody against core protein (2H9)
was generated as described previously (30). Anti-NS5A mouse monoclo-
nal antibody (9E10) was a kind gift from Charles M. Rice (The Rockefeller
University), and anti-NS5A rabbit polyclonal antibody (TB0705#1) was
developed by immunization with the recombinant NS5A protein (8, 40).
For detection of cellular proteins, the following antibodies were used:
mouse monoclonal antibodies directed against Plk1 (Life Technologies)
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Millipore, Te-
mecula, CA); rabbit polyclonal antibodies detecting CKI- (Santa Cruz
Biotechnology, Dallas, TX), CKI-ε (Santa Cruz Biotechnology), cyclinc
AMP (cAMP)-dependent protein kinase catalytic subunit  (PKAC;
Santa Cruz Biotechnology), phosphatidylinositol 4-kinase III (PI4K-
III; Cell Signaling Technology, Danvers, MA), claudin-1 (CLDN1; Life
Technologies), calnexin (Enzo Life Sciences, Farmingdale, NY), and
GM130 (Sigma-Aldrich, St. Louis, MO); and goat polyclonal antibodies
specific for CKII-= (Santa Cruz Biotechnology) and apolipoprotein E
(ApoE; Millipore). Fluorescence-conjugated secondary antibodies, in-
cluding Alexa Fluor 488 goat anti-mouse IgG1 and Alexa Fluor 568 goat
anti-mouse IgG2a, were purchased from Life Technologies. Horseradish
peroxidase (HRP)-conjugated secondary antibodies were from Cell Sig-
naling Technology.
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Protein kinase library and cell-free protein synthesis. The construc-
tion and identity of the 404 cDNAs encoding human protein kinases used
in this study were previously described (41). In vitro transcription and
cell-free protein synthesis were performed as previously reported (42, 43).
Briefly, DNA templates containing a biotin-ligating sequence were ampli-
fied by split-primer PCR with kinase cDNAs and corresponding primers
and then used for protein synthesis with a fully automated protein syn-
thesizer, a GenDecoder (CellFree Sciences, Ehima, Japan). For synthesis
of FLAG-tagged full-length NS5A and domain III proteins derived from
the JFH-1 isolate, DNA templates containing a FLAG sequence were gen-
erated from the NS5A expression plasmid (8) by split-primer PCR and
used with a wheat germ expression kit (CellFree Sciences) according to the
manufacturer’s instructions.
Amplified luminescent proximity homogeneous assay (AlphaScreen).
FLAG-tagged NS5A proteins were mixed with biotinylated kinases in 15
l of reaction buffer (20 mM Tris-HCl [pH 7.6], 5 mM MgCl2, 1 mM
dithiothreitol, and 1 mg/ml bovine serum albumin) in the wells of 384-
well OptiPlates (PerkinElmer, Waltham, MA) and incubated at 26°C for 1
h. The mixture was then added to the detection mixture containing 0.1 l
protein A-conjugated acceptor beads (PerkinElmer), 0.1 l streptavidin-
coated donor beads (PerkinElmer), and 5 g/ml of the anti-FLAG M2
antibody, followed by incubation at 26°C for 1 h. AlphaScreen signals
from the mixture were detected using an EnVision device (PerkinElmer)
with the AlphaScreen signal detection program.
In vitro phosphorylation assay. To obtain purified kinases used for in
vitro phosphorylation assays, DNA templates containing a glutathione
S-transferase (GST)–tobacco etch virus (TEV) sequence were generated
by split-primer PCR with kinase cDNAs and corresponding primers and
used in a cell-free production system with the wheat germ expression kit
as described above. The GST-fusion recombinant proteins were purified
on glutathione-Sepharose 4B (GE Healthcare, Buckinghamshire, United
Kingdom) and then eluted in 40 l of phosphate-buffered saline (PBS)
containing 5 U of AcTEV protease (Life Technologies) in order to cleave
the GST tag from the protein. Biotinylated NS5A proteins were synthe-
sized from DNA templates by using the cell-free BirA system (44). Biotin-
ylated NS5A proteins (40 l) were coupled on 15 l of streptavidin Mag-
nesphere Paramagnetics particles (Promega, Madison, WI) and were
dephosphorylated by using 10 U of lambda protein phosphatase (New
England BioLabs, Ipswich, MA). After washing three times, protein-cou-
pled beads were incubated with 1 l of purified recombinant kinases at
37°C for 30 min in 15 l kinase buffer (50 mM Tris-HCl [pH 7.6], 500
mM potassium acetate, 50 mM MgCl2, and 0.5 mM dithiothreitol) con-
taining 1 Ci of [-32P]ATP. After the reaction, the beads were washed
twice with PBS and then boiled in sample buffer and separated by SDS-
PAGE. Phosphorylated NS5A proteins were visualized via autoradiogra-
phy, and the relative kinase activity of each kinase was determined by
normalizing the band intensity of NS5A to that of NS5A incubated with
dihydrofolate reductase (DHFR). The band intensities were quantified
using Image J software.
Preparation of viral stocks and virus infections. Cell culture-derived
infectious HCV particles (HCVcc) were prepared as described previously
(30, 36). HCVpp consisting of HCV envelope glycoproteins, the murine
leukemia virus Gag-Pol core proteins, and the luciferase transfer vector
and pseudoparticles with the vesiclar stomatitis virus G glycoprotein
(VSV-Gpp) were generated in accordance with methods described previ-
ously (36, 45). Cells seeded onto 24-well plates were transfected with
siRNA and/or plasmid DNA as described below and infected with HCVcc
for 4 h at a multiplicity of infection (MOI) of 0.5 to 5 or with diluted
supernatant containing HCVpp or VSV-Gpp for 3 h. After infection, the
cells were washed with PBS and incubated in fresh complete growth me-
dium for 72 h at 37°C until harvest.
siRNA and plasmid DNA transfections. siRNAs were purchased from
Sigma-Aldrich. The sequences were as follows: CKI-, 5=-GGCUAAAGG
CUGCAACAAAdTdT-3= and 5=-UUUGUUGCAGCCUUUAGCCdTdT-
3=; CKI-1, 5=-GAGAUGAUUUGGAAGCCCUdTdT-3= and 5=-AGGGC
UUCCAAAUCAUCUCdTdT-3=; CKI-2, 5=-GCGAGAACUUCCCAGA
GGAdTdT-3= and 5=-UCCUCUGGGAAGUUCUCGCdTdT-3=; CKI-3,
5=-CUUACAGGAACAGCUAGAUdTdT-3= and 5=-AUCUAGCUGU
UCCUGUAAGdTdT-3=; CKI-ε, 5=-GCGACUACAACGUGAUGGUdTd
T-3= and 5=-ACCAUCACGUUGUAGUCGCdTdT-3=; CKII-=, 5=-CCU
AGAUCUUCUGGACAAAdTdT-3= and 5=-UUUGUCCAGAAGAUCU
AGGdTdT-3=; PKAC, 5=-CAAAUAGAGCAUACUUUGAdTdT-3= and
5=-UCAAAGUAUGCUCUAUUUGdTdT-3=; Plk1, 5=-GUCUCAAGGC
CUCCUAAUAdTdT-3= and 5=-UAUUAGGAGGCCUUGAGACdTdT-
3=; TSSK2, 5=-CACCUACUGACUUUGUGGAdTdT-3= and 5=-UCCAC
AAAGUCAGUAGGUGdTdT-3=; ApoE, 5=-GGAGUUGAAGGCCUACA
AAdTdT-3= and 5=-UUUGUAGGCCUUCAACUCCdTdT-3=; CLDN1,
5=-CAGUCAAUGCCAGGUACGAdTdT-3= and 5=-UCGUACCUGGCA
UUGACUGdTdT-3=; PI4K-III, 5=-CCCUAAAGGCGACGAGAGAdTd
T-3= and 5=-UCUCUCGUCGCCUUUAGGGdTdT-3=. The Mission siRNA
universal negative control (Sigma-Aldrich), which is designed to have no
homology to known gene sequences, was used as a negative control. Si-
lencer Cy3-labeled GAPDH siRNA (Life Technologies) was used to con-
firm siRNA delivery efficiency. Basically, 10 nM siRNAs were transfected
into cells by using Lipofectamine RNAiMax (Life Technologies) accord-
ing to the manufacturer’s recommended procedures. Plk1 siRNA was
transfected at 5 nM because of its cytotoxic effect. Plasmid DNA transfec-
tion was carried out by using TransIT-LT1 transfection reagent (Mirus,
Madison, WI) according to the manufacturer’s protocol. For cotransfec-
tion of siRNA and plasmid DNA, 6 pmol of siRNA and 200 ng of plasmid
DNA were transfected into Huh7.5.1 cells seeded onto a 24-well cell cul-
ture plate by using Lipofectamine 2000 (Life Technologies) according to
the manufacturer’s instructions.
RNA synthesis and electroporation. HCV RNA synthesis and electro-
poration were basically performed as described previously (8). In the con-
text of coelectroporation of siRNA and an in vitro-synthesized sub-
genomic reporter replicon, or full-length HCV RNA, a total of 3  106 to
5  106 Huh-7 cells were electroporated with 120 pmol siRNA and 3 g
SGR-JFH1/Luc RNA or 5 g JFH-1 RNA at 260 V and 950 F. After
electroporation, the cells were immediately transferred onto 24-well or
6-well culture plates or 10-cm cell culture dishes.
Luciferase assay. Cells harboring a subgenomic reporter replicon and
HCVpp-infected cells were lysed in passive lysis buffer (Promega). The
luciferase activity was determined using a luciferase assay system (Pro-
mega) as previously described (46). Secreted GLuc activity was measured
in 25-l aliquots of cell culture supernatants by using the BioLux Gaussia
luciferase assay kit (New England BioLabs) according to the manufactur-
er’s recommended protocol. The luminescence signal was measured on an
Infinite M200 microplate reader (Tecan, Männedorf, Switzerland).
Quantification of HCV core. HCV core protein in cell lysates and
culture supernatants was quantified by using a highly sensitive enzyme
immunoassay as described previously (8).
RNA extraction and RT-qPCR. Total cellular RNA was extracted with
TRIzol reagent (Life Technologies) according to the manufacturer’s in-
structions. Quantification of cellular gene expression was performed by
reverse transcription-quantitative PCR (RT-qPCR) using an Applied Bio-
systems 7500 fast real-time PCR system (Life Technologies) as described
previously (47, 48). Primer/probe sets for qPCR targeting CKI-1, CKI-
2, CKI-3, and TSSK2 genes were selected from validated Assays-on-
Demand products (Life Technologies).
Intra- and extracellular infectivity assays. Intra- and extracellular
infectivities of HCVcc were determined as described previously (8). The
infectious titers were expressed as focus-forming units (FFU)/ml.
Cell viability assay. Cell viability was determined using the CellTiter-
Glo luminescent cell viability assay (Promega) according to the manufac-
turer’s instructions.
Expression of HCV proteins based on vaccinia virus, immunopre-
cipitation, immunoblotting, and silver staining. HCV protein expres-
sion based on vaccinia virus, immunoprecipitation, and immunoblotting
were performed as previously described (8). pJFH1 was transfected into
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cells before infection with vaccinia virus expressing the T7 RNA polymer-
ase. NS5A p58 and p56 protein levels were quantified by densitometry
using Image J software. Silver staining of proteins in polyacrylamide gels
was carried out using a Silver Stain MS kit (Wako Pure Chemical Indus-
tries, Osaka, Japan) in accordance with the manufacturer’s protocol.
Subcellular fractionation analysis. Cells were suspended in homog-
enization buffer (10 mM HEPES-NaOH [pH 7.4], 0.25 M sucrose, and 1
mM EDTA) and disrupted by repeated passages through a 25-gauge nee-
dle. After low-speed centrifugation, postnuclear supernatants were lay-
ered on linear 11-ml iodixanol gradients from 2.5% to 30% and centri-
fuged at 40,000 rpm for 3 h in an SW41 rotor (Beckman, Fullerton, CA).
Thirteen fractions (0.8 ml in each fraction) were collected from the top of
the gradient. Each fraction was concentrated by ultrafiltration units with a
10-kDa molecular mass cutoff (Millipore, Bedford, MA), separated by
SDS-PAGE, and immunoblotted with antibodies specific for NS5A, cal-
nexin, and GM130.
Indirect immunofluorescence and microscopy analyses. Cells incu-
bated for 3 days after infection with HCVcc of JFH-1 were fixed with 4%
paraformaldehyde for 15 min at room temperature. After washing with
PBS, the cells were permeabilized with 0.05% Triton X-100 in PBS for 15
min at room temperature and subsequently incubated in PBS containing
10% goat serum for 1 h. The cells were then costained with antibodies
against core and NS5A, followed by incubation with fluorescent second-
ary antibodies. Cells were counterstained with Hoechst 33342 (Sigma-
Aldrich) to label nuclei and BODIPY 493/503 (Life Technologies) to label
lipid droplets and then mounted in Vectashield (Vector Laboratories,
Burlingame, CA). Subcellular localization of HCV proteins was observed
on a Leica SP2 AOBS laser scanning confocal microscope (Leica, Wetzlar,
Germany). Colocalization of NS5A and LDs or core was evaluated quan-
titatively by using the intensity correlation analysis of the Image J soft-
ware. To statistically compare degrees of colocalization, we determined
the intensity correlation quotient (ICQ) (49). ICQ values are distributed
between 0.5 and 0.5, with a value of 	0 reflecting random staining
and values between 0 and 0.5 versus values between 0 and 0.5 indic-
ative of dependent versus segregated immunolabeling, respectively.
Mass spectrometry analysis. Immunoprecipitated NS5A bands were
excised from the gels after silver staining and destained, followed by in gel
digestion with trypsin in 50 mM ammonium bicarbonate overnight at
30°C. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
analysis was performed on an LTQ Orbitrap Velos hybrid mass spectrom-
eter (Thermo Fisher Scientific, Bremen, Germany) using Xcalibur (ver-
sion 2.0.7), coupled to an UltiMate 3000 LC system (Dionex LC Packings,
Sunnyvale, CA). The Proteome Discoverer software (version 1.3; Thermo
Fisher Scientific) was used to generate peak lists from the raw MS data
files. The resulting peak lists were subsequently submitted to a Mascot
search engine (version 2.4.1; Matrix Science, London, United Kingdom)
and compared against the HCV protein sequences in the NCBI nonredun-
dant protein database (version 20 January 2013; 74,0475 sequences) to
identify peptides. The Mascot search parameters were as follows: two
missed cleavages permitted in the trypsin digestion; variable modifica-
tions including oxidation of methionine, propionamidation of cysteine,
and phosphorylation of serine, threonine, and tyrosine; peptide mass tol-
erance of 
5 ppm; fragment mass tolerance of 
0.5 Da. A minimum
Mascot peptide score of 25 was set for peptide selection.
Statistical analyses. Statistical analyses were performed using the Stu-
dent t test unless otherwise noted. A P level of 0.05 was considered
significant.
RESULTS
A kinome-wide screening of human protein kinases for identi-
fication of NS5A-associated kinases. It has been reported that
some protein kinases directly or stably associate with HCV NS5A
and phosphorylate it in vitro (25, 50, 51). To search comprehen-
sively to identify novel NS5A-associated kinases, a kinome-wide
screening for interactions of full-length NS5A with human kinases
was initially performed. We synthesized 404 human kinases with a
wheat germ cell-free protein production system and screened
them in terms of their association with NS5A by using a high-
throughput assay system based on AlphaScreen technology (Fig. 1A;
FIG 1 Identification of NS5A-associated kinases. (A) AlphaScreen-based protein-protein interaction assay. FLAG-tagged full-length NS5A, and each of 404
biotinylated human protein kinases, which were synthesized in a cell-free protein production system, were mixed with the detection mixture containing
anti-FLAG antibody, protein A-conjugated acceptor beads, and streptavidin-coated donor beads in 384-well plates. Luminescence signals from the mixture were
detected. Ninety-five protein kinases were identified with luminescence signals of 1,300, of which 84 were serine/threonine kinases. The assay was performed
in duplicate for each sample, and data shown are mean values of duplicate experiments. (B) Exemplary autoradiographic images of NS5A phosphorylated in vitro.
Purified kinases were mixed with biotinylated NS5A proteins coupled on streptavidin beads in kinase buffer containing [-32P]ATP. After the reaction, samples
were subjected to SDS-PAGE and autoradiography. The arrows, black arrowheads, and white arrowheads indicate phosphorylated full-length NS5A, phosphor-
ylated NS5A domain III, and autophosphorylated kinases, respectively.
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see also Table S1 in the supplemental material). Ninety-five pro-
teins were selected as those that possibly bind to NS5A under the
cutoff condition of luminescence signals at 1,300. Among them,
84 were serine/threonine kinases, and Plk1 and CKII-=, the cat-
alytic subunit = of CKII whose associations with NS5A have been
reported (25, 50), were found in the group as signals at 3,230
(Plk1) and 5,068 (CKII-=). This suggested that our assay system
is highly reliable for screening the NS5A-kinase interaction.
In vitro phosphorylation of NS5A by the identified NS5A bind-
ing serine/threonine was determined. Each kinase that was syn-
thesized in vitro and purified was incubated with either full-length
NS5A or domain III of NS5A in the presence of [-32P]ATP and
separated by SDS-PAGE. Phosphorylated NS5A proteins were
then visualized by autoradiography (Fig. 1B). The relative kinase
activity was determined by normalizing the band intensity of
phosphorylated NS5A with that of NS5A incubated with DHFR,
which had no kinase activity and was used as a negative control.
Twenty-nine out of 84 serine/threonine kinases were not accu-
rately assessed due to their low levels of expression. As shown in
Table 1, among a total of 55 kinases tested (see Table S2 in the
supplemental material), nine (CKI-, CKI-1, CKI-2, CKI-3,
CKI-ε, CKII-=, PKAC, Plk1, and TSSK2) exhibited efficient
phosphorylation of NS5A, defined as a more-than-4-fold or
8-fold increase in activity against the full-length NS5A or domain
III of NS5A, respectively, compared to the negative control. Con-
sistent with previous reports (9, 25, 50), Plk1 and CKII-= showed
apparent kinase activities against NS5A in vitro.
Identification of an NS5A-associated kinase, CKI-, that is
important for the HCV life cycle. On the basis of the in vitro
screenings, nine candidate kinases were further tested as to whether
they play roles in the HCV life cycle. We conducted siRNA-based
gene silencing of each kinase and assessed its effect on virion pro-
duction. Huh7.5.1 cells were transfected with siRNAs targeting
the kinases and infected with JFH-1 virus at an MOI of 1, 48 h after
siRNA transfection. After an additional 72-h incubation, the viral
core levels and infectious virus yields in cell culture supernatants
were determined. Knockdown efficiencies of the targeted genes at
72 h after JFH-1 infection are shown in Fig. 2A. Efficient knock-
down was confirmed either by immunoblotting or RT-qPCR. Fig-
ure 2B indicates the effects of gene silencing on virus production
(upper panel) and on cell viability by ATP-based luminescence
assays (lower panel). An approximately 30-fold reduction in in-
fectious virus yields was observed following knockdown of ApoE,
which has been shown to have important roles in HCV assembly
and release (52). Among the kinases tested, silencing of CKI-
showed the most profound inhibition of infectious HCV produc-
tion (	40-fold) without cytotoxicity. Knock down of CKII-=
and PKAC led to a moderate reduction in infectious virus pro-





TSSK2 8,310 4.24 14.94
CKII-= 5,068 2.30 8.20
Plk1 3,230 2.70 44.65
CKI-2 2,602 4.31 3.15
CKI-1 2,560 NA 138.69
CKI-3 2,218 0.23 52.51
CKI-ε 2,012 7.95 9.48
PKAC 1,854 0.15 69.54
CKI- 1,354 4.66 1.00
a LU, light units from the AlphaScreen; FL, full-length NS5A; D3, domain III of NS5A.
NA, not assessed due to overlap between purified kinases and NS5A on the gel. The
relative kinase activity is the fold increase of the in vitro activity of each kinase relative
to that of DHFR.
FIG 2 Identification of NS5A-associated kinases involved in the HCV life cycle. (A) siRNA-based gene silencing of NS5A-associated kinases. Huh7.5.1 cells were
transfected with siRNAs targeting the indicated genes and were harvested 5 days later for immunoblotting (IB) and RT-qPCR to confirm knockdown efficiencies.
mRNA levels of target genes relative to GAPDH mRNA were normalized with values for transfection of control siRNAs (siCtrl), which were set at 100%. Results
represent the means 
 standard deviations from three independent transfections of siRNA. Mock represents transfection without siRNA. (B) Infectious HCV
production and cell viability following knockdown of NS5A-associated kinases. Huh7.5.1 cells were infected with JFH-1 virus at an MOI of 1, 2 days after siRNA
transfection. Culture supernatants and cells were harvested 3 days later to determine infectious virus yields (upper panel) and cell viability (lower panel),
respectively. Cell viability for each transfection was normalized to that for mock transfection (mock), which was set at 100%. Results shown represent the
means 
 standard deviations from three independent transfections of siRNA. Mock, transfection without siRNA.
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duction (	10-fold), which was consistent with previous reports
showing that CKII-= and PKA are involved in virion assembly
and viral entry, respectively (9, 53). Knockdown of CKI-ε and
Plk1 also resulted in a moderate decrease in virion production
(	20-fold), but they induced moderate to severe cell toxicity as
well.
Thus, CKI-, which phosphorylates NS5A, had the highest im-
pact on HCV production based on in vitro comprehensive screen-
ings for protein kinases and a subsequent siRNA-based assay.
To further demonstrate that impaired virus production results
specifically from CKI- silencing and is not an off-target effect of
the siRNA, cells were cotransfected with CKI- siRNA and a mu-
tated CKI- expression vector (pCAG-CKI-/m6) that contained
6 base mismatches within the site targeted by the CKI- siRNA
without a change in amino acids, followed by JFH-1 infection at an
MOI of 0.5 on the next day. The cells and culture supernatants
were harvested 3 days later for immunoblotting and titrations of
virus yields, respectively (Fig. 3A). Transfection of the CKI-
siRNA led to a significant reduction in infectious virus yields and
in the p58/p56 ratio of NS5A. Ectopic expression of the siRNA-
resistant CKI-/m6 apparently restored virus yields (P  0.05), as
well as the p58/p56 ratio of NS5A (P  0.05). Similar results re-
garding the p58/p56 ratio were obtained from immunoblot anal-
ysis following vaccinia virus-T7 polymerase-mediated expression
of HCV proteins (Fig. 3B). These results indicated that impaired
virion production and reduced NS5A hyperphosphorylation are
specifically caused by CKI- silencing. Infectious virus yields
showed a closer correlation with the p58/p56 ratio of NS5A than
did the expression level of CKI-, suggesting that the involvement
of CKI- in HCV production is through hyperphosphorylation of
NS5A.
CKI- is mainly involved in virion assembly in the HCV life
cycle. Although it has been reported that CKI- plays roles in the
regulation of HCV RNA replication through NS5A phosphoryla-
tion, experiments addressing its involvement in the viral life cycle
have been performed using the subgenomic replicon system (27).
To determine the basic role of CKI- in the production of infec-
tious HCV, the effect of CKI- silencing on individual steps in the
HCV life cycle was assessed.
First, we used an HCVpp system to analyze viral entry. Two
days after the siRNA transfection, the cells were infected with
HCVpp derived from JFH-1 or VSV-Gpp and were cultured for a
further 3 days (Fig. 4A). Consistent with a previous report (54),
CLDN1 knockdown inhibited HCVpp entry by approximately
70%, but not VSV-Gpp entry, compared to transfection with neg-
ative control siRNA. CKI- silencing did not affect HCVpp or
VSV-Gpp entry, suggesting that CKI- is not required for HCV
entry.
Second, the effect of CKI- knockdown was tested using an
HCV subgenomic replicon system. Three days after the siRNA
transfection, the cells were coelectroporated with the identical
siRNA and JFH-1 subgenomic luciferase reporter replicon RNA,
FIG 3 Restoration of NS5A hyperphosphorylation and infectious virus yields by ectopic expression of siRNA-resistant CKI-. (A) Huh7.5.1 cells were
cotransfected with the indicated siRNAs and plasmid DNAs. The next day, cells were infected with JFH-1 virus at an MOI of 0.5. Culture supernatants and cells
were harvested an additional 3 days later for measurement of virus yields and immunoblotting (IB). The p58/p56 ratios were calculated after quantifying the band
intensities of NS5A. Values shown represent the means 
 standard deviations from three replicate experiments. *, P  0.05; **, P  0.01. (B) Huh-7 cells were
transfected either with CKI- siRNA (siCKI-) or with an irrelevant control siRNA (siCtrl). The next day, cells were retransfected with pJFH1 and pCAG-CKI-
/m6 or empty vector (pCAGGS), followed by infection with vaccinia virus expressing the T7 RNA polymerase at an MOI of 10. NS5A bands were quantified by
densitometric analysis, and the p58/p56 ratios were calculated. Immunoblotting images and values shown are representative of two independent experiments.
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followed by harvesting at different time points (Fig. 4B). The re-
porter luciferase activity at each time point was corrected with the
luciferase value at 4 h posttransfection to normalize transfection
efficiencies. Although efficient knockdown was achieved with
siRNAs (Fig. 4B, left panel), CKI- knockdown led to a marginal
but nonnegligible decrease in the luciferase activity over the indi-
cated time period. In contrast, PI4K-III knockdown, as a positive
control, resulted in a marked decrease (200-fold) in activity
(Fig. 4B, right panel). The effect of CKI- silencing on the repli-
cation of the subgenomic replicon was further analyzed by using
two cell lines derived from genotype 1b (LucNeo#2) (38, 39) and
genotype 2a (SGR-JFH1/LucNeo) (Fig. 4C). Both Huh-7-based
FIG 4 Virion assembly is a primary target of CKI-. (A) Effect of CKI- knockdown on viral entry. Huh7.5.1 cells were transfected with the indicated siRNAs.
Two days later, cells were infected with HCVpp (gray bars) or VSV-Gpp (black bars) and harvested an additional 3 days later for immunoblotting (IB) and
luciferase assays. Values were normalized to the value for transfection with control siRNAs (siCtrl), set at 100%. Values shown represent the means 
 standard
deviations from three independent transfections of siRNA. (B) Transient replication assay for the JFH-1 subgenomic replicon following CKI- knockdown.
Huh-7 cells transfected with the indicated siRNAs were coelectroporated with the identical siRNAs, and JFH-1 subgenomic luciferase reporter replicon RNA, and
harvested at the indicated time points for immunoblotting (IB) and luciferase assays. The luciferase activity at each time point was corrected by the luciferase
value at 4 h posttransfection to normalize transfection efficiencies. Values shown represent the means 
 standard deviations from three replicate experiments.
(C) Effects of CKI- knockdown on replication in replicon cell lines derived from genotypes 1b and 2a. Two cell lines harboring an HCV subgenomic luciferase
reporter replicon, LucNeo#2 (genotype 1b, GT1b) and SGR-JFH1/LucNeo (genotype 2a, GT2a), were transfected with the indicated siRNAs and harvested 3 days
later for immunoblotting (IB) and luciferase assays. Luciferase activities were normalized to the luciferase values for transfection with control siRNA (siCtrl), set
at 100%. Values shown represent the means 
 standard deviations from three independent transfections of siRNA. (D) Effects of CKI- knockdown on viral
assembly and release. Huh7-25 cells transfected with the indicated siRNAs were coelectroporated with the identical siRNAs and JFH-1 RNA. Cells and
supernatants were harvested 3 days later for immunoblotting (IB) and titrations of extracellular and intracellular infectious virus by focus-forming unit (FFU)
assays. Values represent the means 
 standard deviations from three replicate experiments. (E) Effect of CKI- knockdown on the abundance of intracellular
core protein. Amounts of core in cells for which results are shown in panel D were measured. Results represent the means 
 standard deviations from three
replicate experiments. (F) Effect of CKI- knockdown on intracellular infectivity relative to core protein expression. Intracellular infectivity relative to core
expression was determined by normalizing the yield of intracellular infectious virus (shown in panel D) with the amount of intracellular core protein shown in
panel E. Results represent the means 
 standard deviations from three replicate experiments.
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subgenomic replicon cell lines carry a firefly luciferase reporter
gene fused to the neomycin phosphotransferase gene. As shown in
the right panel of Fig. 4C, knockdown of CKI- resulted in a
marked (	65%) decrease in replication of the genotype 1b repli-
con but only a slight (	10%) decrease in the genotype 2a replica-
tion, although knockdown efficiencies of CKI- were sufficient
and comparable in both cell lines (Fig. 4C, left panels). Our result
with the genotype 1b replicon was consistent with a previous re-
port (27). In contrast, the limited impact of CKI- silencing on
the replication of the JFH-1 subgenomic replicon suggests that the
RNA replication step may not be a key role for CKI- in the reg-
ulation of HCV JFH-1 production.
Finally, we focused on the late stages of the HCV life cycle and
analyzed the involvement of CKI- in virion assembly and release
via a single-cycle virus production assay (55), in which Huh7–25
cells lacking CD81 expression were used. Three days posttransfec-
tion with siRNAs, the cells were cotransfected with the identical
siRNAs and JFH-1 RNA by electroporation. The cells and culture
supernatants were harvested after a further 3 days, and titrations
of intra- and extracellular infectious virus were assessed (Fig. 4D
to F). Reduced NS5A hyperphosphorylation was observed follow-
ing CKI- knockdown, but not following ApoE knockdown or
transfection with irrelevant siRNA (Fig. 4D, left panel). Both
CKI- and ApoE knockdown led to an 	10-fold reduction in the
yield of extracellular infectious virus compared to the negative
control. Approximately a 9-fold reduction was found in the yield
of intracellular infectious virus following CKI- knockdown (Fig.
4D, right panel), indicating that CKI- is not required for virus
release from cells. Despite the marked decrease in intracellular
virion yield, CKI- knockdown resulted in only a 1.3-fold reduc-
tion in the abundance of intracellular core protein (Fig. 4E), sup-
porting a limited impact for CKI- knockdown on viral replica-
tion (Fig. 4B). Furthermore, CKI- silencing led to approximately
an 8-fold reduction in the intracellular infectivity relative to core
protein expression, which represents the efficiency of viral assem-
bly expressed as the yield of intracellular infectious virus normal-
ized to the amount of intracellular core protein (Fig. 4F). Collec-
tively, these observations suggest that in the HCV life cycle, CKI-
plays a key role most likely in the assembly of infectious viral
particles.
NS5A hyperphosphorylation mediated by CKI- possibly
contributes to recruitment of NS5A to low-density membrane
structures around LDs in infected cells. It has been demonstrated
that recruitment of NS5A to cytoplasmic low-density membrane
structures surrounding LDs, and the interaction of NS5A with the
core protein at the site, are essential to HCV assembly (7, 8, 56). To
gain mechanistic insight into the function of CKI- in virion as-
sembly, we performed a subcellular fractionation assay and exam-
ined whether NS5A phosphorylation by CKI- contributed to the
subcellular localization of NS5A. Lysates of cells transfected with
JFH-1 RNA in the presence or absence of CKI- silencing (Fig. 5A,
left panel) were fractionated with 2.5 to 30% iodixanol gradients
followed by immunoblotting of the fractions (Fig. 5A, right pan-
els). In control cells (siCtrl), hyperphosphorylated p58 NS5A pre-
dominantly resided in low-density fractions, such as fractions 1 to
3, while hypophosphorylated p56 NS5A localized not only in the
low-density fractions but also in high-density fractions, such as
fractions 11 and 12. In contrast, knockdown of CKI- (siCKI-)
decreased the abundance of hyperphosphorylated NS5A and
NS5A in the low-density fractions. NS5A levels in the high-density
fractions were not reduced by CKI- knockdown. These results
indicate that CKI- is involved in the distribution of NS5A in cells
as well as in its hyperphosphorylation.
We next assessed whether the intracellular localization of
NS5A and its interaction with LDs or the core protein are affected
by CKI- knockdown by using laser-scanning confocal immuno-
fluorescence microscopy. Cells were transfected either with CKI-
siRNA (siCKI-) or with an irrelevant control siRNA (siCtrl),
followed by infection with HCVcc. Efficient knockdown of CKI-
was confirmed by immunoblotting and was associated with de-
creased p58 expression (Fig. 5B). The delivery of siRNA into
nearly 100% of the cells was observed with Cy3-labeled siRNA
(Silencer Cy3-labeled GAPDH siRNA) (Fig. 5C). In siCtrl-trans-
fected cells, NS5A was colocalized or closely associated with LDs.
In contrast, its association with LDs was decreased following
CKI- depletion (Fig. 5D) (P  0.0001 by two-sided Mann-Whit-
ney test). Similarly, NS5A and the core protein were clearly colo-
calized in control cells, while their colocalization was reduced in
CKI- knockdown cells (Fig. 5E) (P  0.0110 by two-sided
Mann-Whitney test). These microscopy findings suggest that
CKI- and/or CKI--mediated hyperphosphorylation of NS5A is
involved in the NS5A-core colocalization at or around LDs in
HCV-infected cells. Taken together with the results of our subcel-
lular fractionation assay (Fig. 5A), it is likely that CKI- plays a
role in recruiting NS5A to low-density membrane structures
around LDs through hyperphosphorylation of NS5A, and it may
facilitate the NS5A-core interaction at these sites.
Identification of potential phospho-acceptor regions for
CKI-. The above results prompted us to identify the phospho-
acceptor sites for CKI- by using a proteomics approach. Lysates
of cells expressing the HCV JFH-1 genome, transfected with either
CKI- siRNA or an irrelevant control siRNA, were immunopre-
cipitated with an anti-NS5A antibody followed by SDS-PAGE
(Fig. 6A). Immunoblotting showed a marked reduction of NS5A
p58 following CKI- knockdown (Fig. 6A, right panel). Silver-
stained gel bands of p58 and p56 (Fig. 6A, left panel) were excised
and subjected to in-gel digestion, followed by mass spectrometry
analysis (Fig. 6B). A total of 629 peptides were identified from
both control NS5A (siCtrl) and NS5A with CKI- knockdown
(siCKI-) after peptide selection with a Mascot peptide score of
25 (see Table S3 in the supplemental material) and yielded 53%
proteome coverage in total (49.4% for control NS5A and 41.8%
for NS5A with CKI- knockdown), as indicated in the upper
panel of Fig. 6B (red letters). Peptides corresponding to domain
III in NS5A were not obtained in this analysis. We identified three
kinds of phosphopeptides (1, GSPPSEASSSVSQLSAPSLR; 2, AP
TPPPR; 3, TVGLSESTISEALQQLAIK [Fig. 6B, upper panel, high-
lighted in green, blue, and yellow, respectively]) (see also Table
S3). However, fine mapping of phosphorylation sites was not
completely successful in this assay, probably due to the low abun-
dance of immunoprecipitated NS5A. We next assessed which pep-
tide contained the potential phospho-acceptor sites for CKI- by
comparing the frequencies of phosphopeptides identified with
and without CKI- knockdown. As shown in the lower panel of
Fig. 6B, the frequency of phosphopeptide 1 relative to the total
number of peptide 1 identified was decreased after CKI- knock-
down (from 26.2% to 19.8%). In contrast, the relative frequencies
of phosphopeptides 2 and 3 were unaffected or increased by
CKI- knockdown. We noted that the threonine residue in pep-
tide 2 is unlikely to be a consensus phosphorylation site of CKI
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(57). Thus, the results suggest that peptide 1 (GSPPSEASSSVSQL
SAPSLR) is the peptide most likely to contain the amino acids
phosphorylated by CKI-.
S225 and S232 are key residues involved in NS5A hyperphos-
phorylation and hyperphosphorylation-dependent regulation
of infectious virus production. Peptide 1 identified above con-
tains eight serine residues that are highly conserved among HCV
isolates and are clustered within LCS I (Fig. 7A). To identify amino
acids responsible for CKI--mediated hyperphosphorylation, we
assessed the impacts of alanine or aspartic acid substitutions for
these 8 serine residues on NS5A hyperphosphorylation and virus
production. An HCV JFH-1 genome with the reporter luciferase,
which enabled us to evaluate viral replication by measuring GLuc
activity, and a series of its NS5A mutated constructs (Fig. 7A) were
generated. Supernatants of cell cultures transfected with the RNA
transcripts were harvested at 4, 24, 48, and 72 h posttransfection
FIG 5 Effects of CKI- knockdown on the subcellular localization of NS5A and its interaction with LDs or core protein. (A) Iodixanol density gradient analysis
(right). Huh7-25 cells transfected with the indicated siRNAs were coelectroporated with the identical siRNAs and JFH-1 RNA. Cell lysates were prepared 3 days
after electroporation and fractionated by iodixanol gradients of 2.5% to 30%. The gradient was collected in 0.8-ml fractions for immunoblotting. Total cell lysates
before fractionation were loaded as input controls. Detected bands in fractions 1 to 3 and in fractions 11 and 12 are enclosed by squares. (Left) Immunoblotting
(IB) results for CKI- 3 days after electroporation. GAPDH was included as a loading control. (B) Immunoblot (IB) of NS5A and CKI- 3 days after HCVcc
infection. GAPDH was included as a loading control. (C) siRNA delivery efficiency. Cy3 fluorescence (red) was observed 3 days after transfection of Silencer
Cy3-labeled GAPDH siRNA. Nuclei were counterstained with Hoechst 33342 (blue). (D) Colocalization of NS5A and LDs. Confocal microscopy images show
cells transfected with either CKI- siRNA (siCKI-) or an irrelevant control siRNA (siCtrl), followed by infection with JFH-1 virus (left). Cells were fixed with
paraformaldehyde 3 days after infection and labeled with an antibody specific for NS5A (red). Cells were counterstained with BODIPY 493/503 (green) to label
lipid droplets and with Hoechst 33342 (blue) to label nuclei. Insets represent enlarged views of portions surrounded by squares. Colocalization of NS5A and LDs
pixels were assessed quantitatively by intensity correlation analysis using ImageJ software (right). Plots shown represent the ICQ obtained from each of 60
NS5A/LD double-positive cells. Bars indicate the median 
 interquartile range of the plots. **, P  0.01 by two-sided Mann-Whitney test. (E) Colocalization of
NS5A and core protein. Confocal microscopy images show cells transfected either with CKI- siRNA (siCKI-) or with a control siRNA (siCtrl), followed by
infection with JFH-1 virus (left). Fixed cells were labeled with antibodies specific for NS5A (red) and core (green). Nuclei were counterstained with Hoechst
33342 (blue) in the merged images. Mag images represent enlarged views of portions surrounded by squares in the merged images. Colocalization of NS5A and
core pixels was assessed quantitatively by intensity correlation analysis using ImageJ software (right). Plots shown represent ICQs obtained from each of 60
NS5A/core double-positive cells. Bars indicate the median 
 interquartile range. *, P  0.05 by two-sided Mann-Whitney test.
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and subjected to the GLuc assay. As shown in the left panel of Fig.
7B, serine-to-alanine substitution at either aa 229 (S229A) or at aa
235 (S235A) resulted in severe reduction in the viral replication.
In contrast, the replication capacities of S222A, S228A, S230A,
and S238A mutant reporter viruses were comparable to that of the
wild type (WT). S225A and S232A mutations led to a slight but
nonnegligible reduction in replication compared to WT. The
phospho-mimetic aspartic acid substitution for aa 235 (S235D)
exhibited a much higher replication capacity (	100-fold) than
S235A, indicating that phosphorylation of S235 is required for
efficient viral replication. In contrast, the replication capacity of
S229D was still more-than-10-fold lower than that of WT, sug-
gesting that introduction of negative charge at this position is not
sufficient to enhance viral replication (Fig. 7B, right panel). S225D
and S232D mutations restored viral replication capacities and ex-
hibited the same replication phenotype as WT. Interestingly,
S222D and S230D resulted in a slight reduction in viral replication
compared to S222A and S230A, consistent with previous reports
(23, 58) (Fig. 7B, right panel).
We next evaluated the effects of the NS5A mutations on infec-
tious virus production by titrations of infectious virus in culture
supernatants of cells transfected with RNA transcripts of JFH-1
viruses at 72 h posttransfection (Fig. 7C). S225A and S232A mu-
tations resulted in 4- and 5-fold reductions in the virus infectious
titer, respectively, compared to WT, while the abilities of S225D
and S232D mutants to produce infectious virus were comparable
to that of WT. Little or no virus production was observed with
S229A, S229D, and S235A mutations, presumably because of their
strong negative impacts on viral replication. A slight reduction in
virus production observed with S230D and S235D mutations was
most likely due to their replication capacities. S222A, S222D,
S228A, S228D, S230A, S238A, and S238D substitutions had no
significant effect on virus production (75% of the WT level).
To determine the effect of the NS5A mutations on NS5A hyper-
phosphorylation, cells expressing JFH-1 viruses were subjected to im-
munoblotting, and the p58/p56 ratio of NS5A was estimated (Fig.
7D). The hyperphosphorylated p58 band of NS5A was clearly de-
tected in cells transfected with WT and S222A, S228A, S230A, and
S238A mutants, which had mean p58/p56 ratios of 0.42, 0.38, 0.35,
0.50, and 0.60, respectively. These p58/p56 ratios were reproducible
in multiple repeated experiments but much lower than the p58/p56
ratios (e.g., 0.93 in siCtrl-transfected cells) in Fig. 3A. This difference
may be attributed to the difference in the way by which HCV was
introduced into cells (virus infection in Fig. 3A and transfection of
viral genome in Fig. 7D and F). The p58 levels were significantly
reduced in cells transfected with S225A or S232A mutants, which had
mean p58/p56 ratios of 0.11 and 0.15, respectively (Fig. 7D). Since the
p58/p56 ratios of the S229A and S235A mutants were not determined
due to low levels of NS5A expression, we reevaluated the p58/p56
ratio of each viral muatant by using a vaccinia virus-T7 polymerase-
mediated protein expression system (Fig. 7E, left panel). Cells trans-
fected with pJFH1 or a series of its NS5A mutants were infected with
vaccinia virus expressing the T7 RNA polymerase and harvested for
immunoblotting. Similar to the results shown in Fig. 7D, the p58/p56
ratios of S225A and S232A mutants were significantly reduced, while
S229A and S235A mutations had no effects (Fig. 7E, right panel). The
hyperphosphorylated band of NS5A was observed in cells transfected
with the S222D, S225D, S228D, S229D, or S230D mutant in both
experimental settings. Interestingly, the S232D, S235D, and S238D
mutations resulted in a slight retardation of p56 mobility (Fig. 7F and
G), consistent with previous reports (58, 59).
Collectively, S225 and S232 are key residues involved in
FIG 6 Identification of NS5A phosphopeptides by a phospho-proteome approach. (A) Silver staining and immunoblotting of immunoprecipitated NS5A.
Huh-7 cells transfected with the indicated siRNAs were coelectroporated with the identical siRNAs and JFH-1 RNA. Cell lysates were prepared 3 days after
electroporation and immunoprecipitated with an anti-NS5A antibody. Immunoprecipitates were subjected to SDS-PAGE, followed by silver staining and
immunoblotting (IB). (B) Phosphopeptide mapping of NS5A by LC-MS/MS analysis. p58 and p56 bands of NS5A were excised from the gel and subjected
to in-gel digestion, followed by mass spectrometry analysis. Red letters represent the amino acids identified. Three kinds of phosphopeptides identified
are highlighted in green (phosphopeptide 1), blue (phosphopeptide 2), and yellow (phosphopeptide 3). The numbers represent amino acid positions
within NS5A.
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NS5A hyperphosphorylation and hyperphosphorylation-de-
pendent regulation of infectious virus production. In addition,
S225A and S232A reproduced the viral phenotype following
CKI- knockdown more precisely than the other serine mu-
tants within the peptide 1 region. It is most likely that S225 and
S232 of NS5A are important for CKI--mediated hyperphos-
phorylation, which is involved in the robust production of in-
fectious HCV.
FIG 7 Effects of mutations at potential CKI- phosphorylation sites on NS5A hyperphosphorylation, viral replication, and infectious virion production. (A)
Highly conserved serine residues located within the LCS I region of NS5A and the sequences of NS5A mutants used. Arrowheads represent putative phosphor-
ylation sites replaced with alanine or aspartic acid. The numbers represent amino acid positions within NS5A. (B) Viral replication. Huh-7 cells were transfected
with the indicated JFH-1-based GLuc reporter constructs, including the WT and its replication-defective mutant (GND). Culture supernatants were harvested
at the indicated time points for luciferase assays. The GLuc activity at each time point was normalized with the activity at 4 h posttransfection, and the fold chnages
are shown. Results represent the means 
 standard deviations from three independent experiments, each performed in triplicate. (C) Infectious virion
production. Huh-7 cells were transfected with the indicated JFH-1 viral RNAs, including the WT and its replication-defective mutant (GND). Culture super-
natants were harvested 3 days (72 h) later for titrations of infectious virus in a focus-forming unit (FFU) assay. The infectious virus yield of each NS5A mutant
was normalized with that of JFH-1 WT, which was set at 100%. Results represent the means 
 standard deviations from multiple independent experiments, each
performed at least in triplicate. (D) Immunoblot of NS5A in lysates of cells transfected with JFH-1 viral RNAs carrying the indicated serine-to-alanine mutations
(left). GAPDH is a loading control. The p58/p56 ratio of each virus was determined by carrying out densitometric analysis of NS5A bands (right). Results shown
represent the means 
 standard deviations from multiple independent experiments. *, P  0.05, compared to WT. N.D., not determined, due to low levels of
expression. (E) Vaccinia virus-T7 polymerase-mediated expression of NS5A in cells transfected with pJFH1 carrying the indicated serine-to-alanine mutations
(left). NS5A bands were quantified by densitometric analysis, and p58/p56 ratios were calculated (right). Data shown represent the means 
 standard deviations
from multiple independent experiments. *, P  0.05; **, P  0.01 (versus WT). (F) Immunoblot of NS5A in lysates of cells transfected with JFH-1 viral RNA
carrying the indicated serine-to-aspartic acid mutation. GAPDH was included as a loading control. The p58/p56 ratio of each virus was determined by carrying
out densitometric analysis of NS5A bands. Results shown represent the means 
 standard deviations from multiple independent experiments. N.D., not
determined, due to the poor separation of p58 and p56 bands. (G) Vaccinia virus-T7 polymerase-mediated expression of NS5A in cells transfected with pJFH1
carrying the indicated serine-to-aspartic acid mutation. NS5A bands were quantified by densitometric analysis, and p58/p56 ratios were calculated. Data shown
are representative of two independent experiments. N.D., not determined, due to the poor separation of p58 and p56 bands. S and L in panels D and F represent
short exposure and long exposure, respectively.
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DISCUSSION
Phosphorylation at serine and threonine residues in HCV NS5A is
critical for regulation of the viral life cycle, including genome rep-
lication and infectious virus assembly (8, 9, 14, 16–18, 59–61).
Several serine/threonine protein kinases have been identified as
enzymes that potentially phosphorylate NS5A (9, 25, 26, 28, 50,
51). To our knowledge, however, this study is the first to identify
through a kinome-wide screening protein kinases that interact
with and phosphorylate NS5A. The in vitro AlphaScreen and
phosphorylation assays, followed by RNAi screening on the
HCVcc system, identified CKI- as a major NS5A-associated ki-
nase involved in NS5A hyperphosphorylation and the production
of infectious virus.
In a previous study, CKI- was reported to be involved in the
replication of the subgenomic replicon derived from genotype 1b,
with evidence that attenuation of CKI- expression inhibited viral
RNA replication up to 60% 5 days after the CKI- knockdown
(27). However, our study with the HCVcc system, as well as de-
tailed analyses dissecting individual steps in the HCV life cycle,
revealed that virion assembly is more affected by CKI- silencing
than is viral genome replication. It is highly likely that the CKI--
mediated hyperphosphorylation of NS5A plays a role in recruiting
NS5A to low-density membrane structures around LDs, leading
to the acceleration of the early step(s) of virus particle formation.
Mutagenesis analyses of putative CKI- phosphorylation sites
identified by a phospho-proteomic approach demonstrated that
serine-to-alanine substitution at aa 225 or aa 232 in NS5A did to
some extent reproduce the viral phenotype following CKI-
knockdown, indicating that S225 and S232 may be key residues for
CKI--mediated NS5A hyperphosphorylation and regulation of
virion assembly.
It is commonly held that HCV replication is regulated through
the tight and delicate control of the ratio between p58 and p56
levels. Adaptive mutations or kinase inhibitors, which reduce
NS5A hyperphosphorylation, enhance the HCV RNA replication
of genotype 1 isolates, possibly by modulating its interaction with
the host vesicle-associated membrane protein-associated protein
subtype A (VAP-A), which is an essential factor for HCV replica-
tion (17–19, 24). In contrast, reduction of NS5A hyperphospho-
rylation by RNAi targeting protein kinases results in inhibition of
the replication of genotype 1 adaptive replicons, indicating a role
for p58 in efficient viral replication (25, 27). Impaired RNA rep-
lication resulting from reduced NS5A hyperphosphorylation has
also been reported in the case of JFH-1 or JFH-1-based recombi-
nant virus (25, 58–60). Consistent with a previous report (27), we
found that CKI- depletion inhibited the replication of the geno-
type 1b subgenomic replicon LucNeo#2, which carries the adap-
tive S2204R mutation in NS5A (38, 39) (Fig. 4C). Our transient-
replication assay with the JFH-1 subgenomic replicon showed a
slight but significant reduction in replication following CKI- de-
pletion (Fig. 4B). However, CKI- silencing did not affect RNA
replication in SGR-JFH1/LucNeo cells, where the JFH-1 sub-
genomic replicon stably replicates (Fig. 4C). Thus, the involve-
ment of CKI- in HCV RNA replication might be genotype or
isolate dependent. We observed a difference in the replication
capacity following CKI- knockdown between transient and sta-
ble replication of JFH-1 replicons (Fig. 4B and C). A moderate
reduction of replication was also detected when the JFH-1 genome
carrying the S225A or S232A mutation was transiently transfected
(Fig. 7B). One may infer that CKI- is involved in the initiation of
viral RNA replication rather than in its maintenance.
Our intra- and extracellular infectivity assays following CKI-
depletion suggested that CKI- primarily targets virion assembly
in the HCV life cycle (Fig. 4D to F), although a slight but nonneg-
ligible negative effect of CKI- knockdown on viral replication
was observed (Fig. 4B). It is accepted that the assembly of HCV
particles requires recruitment of NS proteins, including NS5A as
well as structural proteins, to cytoplasmic membrane structures
around LDs, leading to an interaction between NS5A and the core,
which is important for efficient encapsidation of the viral genome
(7, 8, 56). To understand how CKI- is involved in virion assem-
bly, we performed a subcellular fractionation assay and immuno-
fluorescence confocal microscopy. Our subcellular fractionation
assay clearly showed that hyperphosphorylated NS5A, p58, is
mainly localized in low-density membrane fractions, while hypo-
phosphorylated NS5A, p56, prefers high-density fractions. NS5A
abundance in lighter fractions was decreased following CKI- de-
pletion (Fig. 5A). These results are supported by microscopic
analyses that demonstrated that CKI- silencing reduced colocal-
ization of NS5A with LDs and the core (Fig. 5D and E). We tried to
confirm the interaction of NS5A and core in HCVcc-infected cells
that had been transfected with CKI- siRNA or irrelevant siRNA.
However, the interaction was not observed under this condition,
presumably because immunoprecipitated NS5A and/or core was
not abundant enough to assess their coimmunoprecipitation in
siRNA-transfected cells. Alternatively, we assessed the interaction
in Huh-7 cells coexpressing core and NS5A, although no p58 form
(no functional NS5A) was detected in this setting. We clearly de-
tected the interaction of NS5A and core in this experiment and
found that CKI- depletion had no significant effect on this inter-
action (data not shown). Taken together with the results of con-
focal microscopy (Fig. 5E), this finding might suggest that both (i)
phosphorylation of serine residues in the C terminus of NS5A,
which is involved in the generation of basally phosphorylated
NS5A, as shown previously (8), and (ii) CKI--mediated hyper-
phosphorylation, in which serine residues in the LCS I region are
mainly involved, are important for an efficient interaction be-
tween NS5A and core in HCV replicating cells. Collectively, CKI-
-mediated hyperphosphorylation of NS5A may contribute to an
increase in the local concentration of NS5A at low-density mem-
brane structures around LDs rather than in facilitating the physi-
cal interaction of NS5A and core. The relationship between the
phosphorylation status of NS5A and its localization on cellular
membranes has been previously reported. Miyanari et al. showed
that mutated NS5A expressed from JFH-1 variants (JFH1AAA99
and JFH1AAA102 in their report), whose p58/p56 ratios were lower
than that of wild-type virus, was not recruited to LDs (56). Qiu et
al. fractionated lysates from replicon cells and demonstrated that a
substantial amount of hyperphosphorylated NS5A was detected
in lighter fractions. Treatment with an NS5A inhibitor, BMS-
790052, reduced hyperphosphorylation of NS5A and concomi-
tantly decreased the overall amount of NS5A in low-density mem-
brane fractions (62). These findings raise questions about the
regulatory mechanism(s) of the subcellular localization of NS5A,
especially at low-density membrane structures. The above-men-
tioned NS5A mutants, JFH1AAA99 and JFH1AAA102, have triple al-
anine substitutions for the APK sequence at aa 99 to 101 and the
PPT sequence at aa 102 to 104 in NS5A, respectively, but neither is
likely to be a CKI recognition site. In addition, the NS5A inhibitor
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has no inhibitory effect on CKI activity (62). Thus, it appears that
two or more kinds of serine/threonine-specific protein kinases,
including CKI-, participate in NS5A phosphorylation that is im-
portant for the regulation of its subcellular distribution. It is
tempting to speculate that host factors involved in membrane
trafficking or lipogenesis possibly interact with NS5A in a phos-
phorylation-dependent manner and facilitate recruitment of
NS5A to low-density membrane structures surrounding LDs. Al-
though further study is needed to validate this speculation, NS5A-
interacting factors, such as VAP-A and diacylglycerol acyltrans-
ferase-1 (19, 63, 64), might be candidates for involvement in the
regulation of this process.
To identify potential phospho-acceptor sites for CKI-, a
phospho-proteome analysis was carried out with NS5A isolated
from HCVcc-infected cell lines with and without CKI- knock-
down (Fig. 6). Three kinds of phosphopeptides were identified out
of a total of 629 peptides after peptide selection, although fine
mapping of the phosphorylation sites was not completely success-
ful. Among them, only the relative frequency of phosphopeptide 1
(GSPPSEASSSVSQLSAPSLR) was decreased after CKI- knock-
down, suggesting the possibility that peptide 1 contains amino
acids phosphorylated by CKI-. Serine residues in peptide 1,
which are well conserved among HCV genotypes, matched the
consensus sequences for CKI--mediated phosphorylation (57).
In contrast, a threonine residue in peptide 2 is not conserved and
does not match the consensus sequences for phosphorylation by
CKI-. The frequency of phosphopeptide 3 was unchanged with
and without CKI- knockdown (0.1% versus 0.1%). Further mu-
tagenesis analyses targeting the peptide 1 region suggested that
S225 and S232 are possible CKI- phosphorylation sites involved
in NS5A hyperphosphorylation and infectious virus production,
because alanine substitution for either of these serine residues
reproduced the viral phenotype after CKI- knockdown more
accurately than the other mutants within the peptide 1 region (Fig.
7B to E). The S229A and S235A mutations severely impaired viral
replication, suggesting that phosphorylation at S229 and S235 is
essential for efficient viral replication (Fig. 7B). However, the
HCV protein expression assay using vaccinia virus expressing the
T7 RNA polymerase revealed that phosphorylation of these resi-
dues is not involved in NS5A hyperphosphorylation (Fig. 7E). In
the case of genotype 1 isolates, NS5A mutations that reduce hy-
perphosphorylation enhanced viral RNA replication (17, 18).
However, this was not the case for the S225A or S232A mutation in
genotype 2a. In addition, S229A and S235A mutations in genotype
1b (Con1) markedly enhance viral replication (18), but the same
mutations are lethal in genotype 2a. S232 has been shown to be a
potential phosphorylation site for CKI- by a peptide-based ki-
nase assay in vitro (28). However, the present study is the first to
demonstrate the significance of phosphorylation at S225 and S232
in infectious virus production. The sequence coverage of NS5A by
our mass spectrometry analysis was less than 60% and was espe-
cially low in domain III of NS5A (Fig. 6B). We cannot exclude the
possibility of the presence of additional CKI- phosphorylation
sites in NS5A.
Recently, two cellular kinases involved in the regulation of
NS5A phosphorylation have been identified. PI4K-III is essential
for HCV replication (65–70) and catalyzes the synthesis of phos-
phatidylinositol 4-phosphate accumulating in HCV replicating
cells through its enzymatic activation resulting from an interac-
tion with NS5A (71, 72). PI4K-III directly interacts with the
C-terminal end of NS5A domain I, and NS5A–PI4K-III binding
is essential for viral replication. Its depletion resulted in a relative
increase of p58 abundance, while overexpression of enzymatically
active PI4K-III increased the relative abundance of p56 (73).
Plk1 has been shown to play a role in viral replication through
hyperphosphorylation of NS5A (25). Plk1 was coimmunoprecipi-
tated with NS5A, and knockdown of Plk1 or treatment with a
specific inhibitor decreased both NS5A hyperphosphorylation
and HCV replication. Since the recognition sites for CKI-, PI4K-
III, and Plk1 have been assumed to be spatially close to each
other (25, 28, 73), it is interesting to analyze their interactive ac-
tions in regard to regulation of NS5A phosphorylation.
The exquisite balance between the two different phosphory-
lated forms of NS5A has been proposed to regulate the HCV life
cycle; basally phosphorylated p56 abundance is hypothetically in-
volved in viral RNA replication, and hyperphosphorylated p58 is
required for virion assembly (9, 17, 18, 73, 74). However, this
hypothesis has not yet been fully proven. Our results here provide
strong evidence supporting the involvement of NS5A hyperphos-
phorylation in viral assembly and that of CKI- in mediating this
process. These results not only contribute to a better understand-
ing of the regulatory details of the HCV life cycle but also illumi-
nate targets for potential antiviral strategies.
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